Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model

dc.contributor.authorAbeysekera, Irushi
dc.contributor.authorThomas, Jared
dc.contributor.authorGeorgiadis, Taxiarchis M.
dc.contributor.authorBerman, Alycia G.
dc.contributor.authorHammond, Max A.
dc.contributor.authorDria, Karl J.
dc.contributor.authorWallace, Joseph M.
dc.contributor.authorRoper, Randall J.
dc.contributor.departmentBiology, School of Scienceen_US
dc.date.accessioned2020-02-06T15:46:56Z
dc.date.available2020-02-06T15:46:56Z
dc.date.issued2016-04
dc.description.abstractSCOPE: Down syndrome (DS), caused by trisomy of human chromosome 21 (Hsa21), is characterized by a spectrum of phenotypes including skeletal abnormalities. The Ts65Dn DS mouse model exhibits similar skeletal phenotypes as humans with DS. DYRK1A, a kinase encoded on Hsa21, has been linked to deficiencies in bone homeostasis in DS mice and individuals with DS. Treatment with Epigallocatechin-3-gallate (EGCG), a known inhibitor of Dyrk1a, improves some skeletal abnormalities associated with DS in mice. EGCG supplements are widely available but the effectiveness of different EGCG-containing supplements has not been well studied. METHODS AND RESULTS: Six commercially available supplements containing EGCG were analyzed, and two of these supplements were compared with pure EGCG for their impact on skeletal deficits in a DS mouse model. The results demonstrate differential effects of commercial supplements on correcting skeletal abnormalities in Ts65Dn mice. Different EGCG-containing supplements display differences in degradation, polyphenol content, and effects on trisomic bone. CONCLUSION: This work suggests that the dose of EGCG and composition of EGCG-containing supplements may be important in correcting skeletal deficits associated with DS. Careful analyses of these parameters may lead to a better understanding of how to improve skeletal and other deficits that impair individuals with DS.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationAbeysekera, I., Thomas, J., Georgiadis, T. M., Berman, A. G., Hammond, M. A., Dria, K. J., … Roper, R. J. (2016). Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model. Molecular nutrition & food research, 60(4), 717–726. doi:10.1002/mnfr.201500781en_US
dc.identifier.urihttps://hdl.handle.net/1805/21998
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/mnfr.201500781en_US
dc.relation.journalMolecular Nutrition & Food Researchen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectDown syndromeen_US
dc.subjectEpigallocatechin-3-gallateen_US
dc.subjectMouse modelen_US
dc.subjectSkeletal deficitsen_US
dc.subjectSupplementsen_US
dc.titleDifferential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse modelen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-769065.pdf
Size:
423.61 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: